IMMU 114

Drug Profile

IMMU 114

Alternative Names: hL243; IMMU114

Latest Information Update: 12 Dec 2016

Price : $50

At a glance

  • Originator Immunomedics
  • Class Antibodies; Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Antigen-presenting-cell-modulators; HLA-DR antigen modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Chronic lymphocytic leukaemia; Non-Hodgkin's lymphoma
  • Preclinical Acute lymphoblastic leukaemia
  • Discontinued Graft-versus-host disease

Most Recent Events

  • 06 Dec 2016 Pharmacodynamics data from preclinical studies in Haematological malignancies presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2016)
  • 02 Aug 2016 Phase-I development is ongoing for Chronic lymphocytic leukemia and Non-Hodgkin's Lymphoma in USA (NCT01728207; Immunomedics pipeline, August 2016)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Chronic-lymphocytic-leukaemia(Second-line therapy or greater) in USA (SC, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top